Received by email:

File: Imagin - News Release - Continuation of PP - Nov 1 2016(00619484x9DEBD) (2).doc



CSE Symbol: IME
OTC PINK Symbol: IMEXF
Frankfurt/Stuttgart Stock Exchanges: DPD2

 
NR-2016-IME-23

 
 
Imagin Medical Announces Continuation of Private Placement

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care
---> for urologists in the early detection of bladder cancer through endoscopes.
    
Vancouver, B.C. and Boston, MA, November 1, 2016 - Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart St
--->ock Exchanges: DPD2) (the "Company") announces its intention to continue its non-brokered private placement announced 
--->September 14, 2016 to raise $800,000 through the distribution of units ("Units") at $0.08 per Unit.
Each Unit will consist of one common share and one common share purchase warrant; each warrant entitling the holder to
---> acquire one additional common share at $0.12 in the first 12 months, and at $0.16 in the 12 months thereafter.  
In addition to relying on the usual exemptions, the placement will be available to all persons who held common shares 
--->of the Company as of October 31, 2016 (the record date).  If aggregate subscriptions for Units from existing sharehold
--->ers exceed the maximum number of Units available, the Company will allocate Units on a proportionate basis as to each 
--->subscriber's holdings of the Company's shares as of the record date. 
Finder's fees may be paid, in accordance with Canadian Securities Exchange policies.  Closing of the placement will be
---> subject to making applicable filings with the CSE.
Proceeds from the placement will be used for general working capital purposes, including advancing the development of 
--->imaging solutions for the early detection of cancer through the use of endoscopes.

About Imagin Medical  
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Co
--->mpany believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder c
--->ancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a gr
--->eater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive
---> imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical
--->.com.

ON BEHALF OF THE BOARD:
Jim Hutchens
President & CEO

For further information, contact:
Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: billgaline@gmail.com

CAUTIONARY DISCLAIMER STATEMENT:  The Canadian Securities Exchange has not reviewed and does not accept responsibility
---> for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization an
--->d regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are ofte
--->n identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements
---> other than statements of historical fact, included in this release are forward-looking statements that involve risks 
--->and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and fut
--->ure events could differ materially from those anticipated in such statements. Important factors that could cause actua
--->l results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Ca
--->nadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securiti
--->es regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be in
--->correct. Events or circumstances may cause actual results to differ materially from those predicted, as a result of nu
--->merous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company.
---> The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although co
--->nsidered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ 
--->materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified b
--->y this cautionary statement. The forward-looking statements contained in this news release are made as of the date of 
--->this news release and the Company will update or revise publicly any of the included forward-looking statements as exp
--->ressly required by applicable law.


File: Imagin - News Release - Continuation of PP - Nov 1 2016(00619484x9DEBD) (2).pdf

890 West Pender Street, Suite 600                                                                       133 Hampshire 
--->Road
Vancouver, British Columbia                                                                             Wellesley, MA,
---> 02481, USA
Canada V6C 1J9                                                                                          617-571-6006
778-998-5000                                                                                            www.imaginmedi
--->cal.com




      CSE Symbol: IME                                                                              NR-2016-IME-23
      OTC PINK Symbol: IMEXF
      Frankfurt/Stuttgart Stock Exchanges: DPD2



                       Imagin Medical Announces Continuation of Private Placement
      Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard o
--->f
      care for urologists in the early detection of bladder cancer through endoscopes.


      Vancouver, B.C. and Boston, MA, November 1, 2016   Imagin Medical (CSE: IME) (OTC PINK:
      IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the "Company") announces its intention to
      continue its non-brokered private placement announced September 14, 2016 to raise $800,000 through
      the distribution of units ("Units") at $0.08 per Unit.

      Each Unit will consist of one common share and one common share purchase warrant; each warrant
      entitling the holder to acquire one additional common share at $0.12 in the first 12 months, and at $0.16
      in the 12 months thereafter.

      In addition to relying on the usual exemptions, the placement will be available to all persons who held
      common shares of the Company as of October 31, 2016 (the record date). If aggregate subscriptions for
      Units from existing shareholders exceed the maximum number of Units available, the Company will
      allocate Units on a proportionate basis as to each subscriber's holdings of the Company's shares as of
      the record date.

      Finder's fees may be paid, in accordance with Canadian Securities Exchange policies. Closing of the
      placement will be subject to making applicable filings with the CSE.

      Proceeds from the placement will be used for general working capital purposes, including advancing
      the development of imaging solutions for the early detection of cancer through the use of endoscopes.

      About Imagin Medical
      Imagin Medical is developing imaging solutions for the early detection of cancer through the use of
      endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin's
      initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S.,
      and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the
      Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based
      upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.


      ON BEHALF OF THE BOARD:
      Jim Hutchens
      President & CEO




      {00619484;1}
 For further information, contact:
Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: billgaline@gmail.com

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization an
--->d
regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often
identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements o
--->ther
than statements of historical fact, included in this release are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future
events could differ materially from those anticipated in such statements. Important factors that could cause actual re
--->sults
to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Sec
--->urities
Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of
numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the
Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results
may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly
qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of t
--->he
date of this news release and the Company will update or revise publicly any of the included forward-looking statement
--->s
as expressly required by applicable law.




{00619484;1}